Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and clinical activity of EIK1001, a drug that targets Toll like receptor 78, given intravenously with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer NSCLC. This global, multicenter, double-blind, placebo-controlled study involves participants who have not received prior systemic therapy and aims to assess treatment effects in both squamous and non-squamous NSCLC types. The trial is conducted in two phases Phase 2 and Phase 3 and includes dose optimization, dose expansion, and confirmatory hypothesis testing. Participants are randomly assigned to one of three groups EIK1001 at one of two selected doses plus standard chemotherapy and pembrolizumab, or placebo plus standard chemotherapy and pembrolizumab. Chemotherapy regimens differ based on tumor histology, with pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and carboplatin plus paclitaxel or nab-paclitaxel for squamous NSCLC. Treatments are administered intravenously, and the study is designed to evaluate safety and efficacy over time. During the study, participants undergo regular assessments to monitor progression-free survival, overall survival, and objective response, which are tracked for up to 6 to 10 years depending on the measure. Additional evaluations include adverse event incidence and duration of response. Participants are monitored closely with clinical visits throughout the study period, which may last several years, to ensure safety and collect data on treatment effects.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are investigating whether patients with locally advanced cervical cancer who still have detectable cell-free human papillomavirus DNA cfHPV-DNA in their plasma after standard treatment may benefit from additional chemotherapy. This trial is a prospective, randomized, multicenter clinical study designed to evaluate adjuvant chemotherapy based on this biomarker. The study focuses on patients who have undergone chemoradiotherapy and have persistent cfHPV-DNA, as this may indicate ongoing disease activity. Participants first receive standard treatment with concomitant chemoradiotherapy, including doses of radiation and weekly cisplatin. Four weeks after completing this treatment, a blood test is conducted to detect cfHPV-DNA in plasma. Patients with positive cfHPV-DNA results are randomly assigned to either receive two additional cycles of adjuvant chemotherapy with cisplatin and gemcitabine or to be monitored without further chemotherapy. Patients in both groups undergo regular follow-up every four months, including plasma cfHPV-DNA testing, CT scans of the chest, MRI scans of the abdomen and pelvis, and clinical and gynecological exams. During the study, participants are closely monitored for progression-free survival, overall survival, treatment response, quality of life, and any toxic effects of treatment. Follow-up assessments occur at regular intervals from 7 to 120 days after treatment. The total duration of participant involvement varies based on follow-up schedules. The study uses a single-blind design and randomized allocation to ensure scientific rigor while maintaining patient safety throughout the trial period.
Actively Recruiting
Researchers are evaluating a treatment for advanced breast cancer characterized by positive estrogen receptors, negative HER2 status, and mutations in the ESR1 gene. This study focuses on patients whose cancer has progressed despite prior endocrine therapy and treatment with CDK46 inhibitors. The main goal is to assess how well the combination of elacestrant and everolimus works compared to elacestrant alone in controlling the disease. Participants will be randomly assigned to one of two groups. One group receives daily oral doses of elacestrant and everolimus, while the other receives elacestrant plus a placebo resembling everolimus. Treatment continues in 28-day cycles until the disease progresses, unacceptable side effects occur, or other reasons lead to stopping treatment. After stopping, patients enter a follow-up period lasting up to 12 months where survival and new treatments are tracked every three months. During the study, patients will undergo tumor assessments, clinical evaluations, and quality-of-life questionnaires. Researchers will monitor treatment effects, side effects, and changes in health status. Safety is closely observed through regular tests including blood work and heart function monitoring. The total participation duration may extend up to about a year from treatment start to study completion.
Actively Recruiting
Researchers are studying neuroendocrine carcinomas NEC, including both pulmonary and extra-pulmonary types, in Latin America to better understand patient treatment patterns and outcomes. This observational, retrospective study aims to fill gaps in knowledge about NEC in Brazil, Mexico, Argentina, and Peru by analyzing medical records. The study is non-interventional, meaning patients receive their usual care while data is collected for research purposes. The study collects detailed information from patient medical records, including demographics, diagnosis methods, tumor characteristics, treatments received such as surgery, chemotherapy, and radiotherapy, and disease progression. Data covers patients diagnosed between August 2014 and August 2024. No experimental treatments are given, and patient care follows standard clinical practice at each site. Participants data is gathered through an electronic system without requiring additional study visits, except for consent if needed. Researchers will evaluate treatment patterns, survival outcomes like event-free survival and progression-free survival, and the expression of the DLL-3 marker over an average follow-up of 24 months. The study will help improve understanding of NEC management and outcomes in the region.
Actively Recruiting
Researchers are evaluating the effectiveness of saruparib AZD5305 combined with camizestrant compared to physicians choice of CDK46 inhibitors plus endocrine therapy in patients with BRCA1, BRCA2, or PALB2 mutated, hormone receptor-positive, HER2-negative advanced breast cancer. This phase III study aims to determine which treatment better controls disease progression in this specific patient population. Participants will be randomly assigned to one of four treatment groups saruparib plus camizestrant physicians choice CDK46 inhibitor plus endocrine therapy physicians choice CDK46 inhibitor plus camizestrant or saruparib plus physicians choice endocrine therapy. Treatments are given orally or by injection as appropriate and will continue until the disease progresses, unacceptable side effects occur, or participants choose to stop treatment. During the study, participants will have regular assessments to evaluate disease progression, survival, response to treatment, and quality of life. Researchers will monitor drug levels in the blood and collect tissue samples to support diagnostic development. The study may last up to several years, with ongoing safety and efficacy evaluations to understand the impact of these treatments on advanced breast cancer.
Actively Recruiting
Researchers are evaluating treatments for participants with metastatic colorectal cancer who have a specific KRAS p.G12C mutation and have not received prior treatment. The study compares progression-free survival between two groups one receiving sotorasib, panitumumab, and FOLFIRI, and the other receiving FOLFIRI with or without bevacizumab-awwb. This is a phase 3 randomized trial aiming to understand which combination better manages the disease. Participants in one group take sotorasib daily as an oral tablet while receiving panitumumab and FOLFIRI every two weeks through intravenous infusions. The other group receives FOLFIRI every two weeks, with or without bevacizumab-awwb, also given by intravenous infusion every two weeks. The study treatments continue according to these schedules to compare their effects. Throughout the trial, participants will undergo assessments to measure progression-free survival using RECIST v1.1 criteria for up to approximately three years. Additional outcomes like overall survival, response rates, duration of response, and safety events are monitored for up to five years. Researchers will collect blood samples to measure sotorasib levels during early treatment cycles. Participants are closely observed through scheduled visits and tests to evaluate treatment effects and safety over the study duration.